MedDataX Logo

Evaluation of Information Displays A Paper & Pencil, Computer, Simulator, and ICU Based Study

NCT ID: NCT00714350

Last Updated: 2014-12-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

32 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-07-31

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our objective is to develop intuitive, meaningful and ergonomically efficient informative displays specific to the user's domain. Specifically we aim to enhance and refine the display prototype of ABG information to include gas-exchange, acid-base balance, lung mechanics, ventilation, oxygenation, and metabolism information.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To create an intuitive and meaningful visualization of Arterial Blood Gas (ABG) variables, it is necessary to address usability, ergonomics, domain specific, and expertise specific issues and concerns. Our objective is to develop intuitive, meaningful and ergonomically efficient informative displays specific to the user's domain. Specifically we aim to enhance and refine the display prototype of ABG information to include gas-exchange, acid-base balance, lung mechanics, ventilation, oxygenation, and metabolism information.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Information Display situational awareness Create intuitive visualization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Simulator Group - With Display

ICU nurses who viewed the new ICU display visualization

New ICU Display Visualization

Intervention Type BEHAVIORAL

Simulator Group - Without Display

ICU nurses who did not view the new ICU display visualization, but instead viewed a traditional "spreadsheet" style presentation of ICU trends of data

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

New ICU Display Visualization

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion Criteria: ICU nurses Exclusion Criteria: All participants were screened and excluded from participation if they had previously participated in any of graphical display design and feedback sessions when developing the ICU display.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role collaborator

University of Utah

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Noah Syroid

M.S.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Behrens

Role: PRINCIPAL_INVESTIGATOR

University of Utah

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2R44HL079783-02A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

23126

Identifier Type: -

Identifier Source: org_study_id